FTWA
AZN icon

Fifth Third Wealth Advisors’s AstraZeneca AZN Stock Holding History

Fifth Third Wealth Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,123
Closed -$222K – 993
2026
Q1 		$222K Buy
+1,123
New +$217K 0.01% 751
2025
Q1 		– Sell
-2,060
Closed -$270K – 714
2024
Q4 		$270K Sell
2,060
-605
-23% -$84.7K 0.01% 537
2024
Q3 		$415K Buy
+2,665
New +$430K 0.03% 357

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fifth Third Wealth Advisors's AZN Position: Q2 2026 in Review

Fifth Third Wealth Advisors sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 1,123 shares — an estimated $222K sold.

Fifth Third Wealth Advisors first reported a position in AZN in Q3 2024 and held it in 3 quarters. The position peaked at $415K in Q3 2024. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Fifth Third Wealth Advisors reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • Fifth Third Wealth Advisors sold 1,123 AstraZeneca shares in Q2 2026, an estimated $222K.
  • Fifth Third Wealth Advisors first reported a position in AstraZeneca in Q3 2024 and held it in 3 quarters.
  • Fifth Third Wealth Advisors's AstraZeneca position peaked at $415K in Q3 2024.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.